Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Epistemonikos ID: 95a7a86b6f95816498ddd0ac0b0dc542777febc5
First added on: May 10, 2024